Puma Biotechnology Inc (PBYI) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Puma Biotechnology Inc stock $9.62, price $8.25, upside +16.6%, quality 62 out of 100. Rating: undervalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range $1.64 – $11.26 · fair‑value band $7.22 – $11.96 · the $8.25 price screens below the $9.62 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.
Follow Puma Biotechnology in your weekly email
Every Wednesday you see whether Puma Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
Show moreShow less
It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks.
The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Stock analysis
Puma Biotechnology Inc (PBYI) currently trades at $8.25, while our model-based Fair Value estimate is $9.62, implying the stock looks roughly 14% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $11.28 per share, and 15 of the 22 models we run sit above the $8.25 price.
Bear case: the Asset-Based group reads lowest at $1.49, and 7 of the 22 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $7.22 (bear) to $11.96 (bull), the price of $8.25 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Puma Biotechnology Inc reported revenue of $228M in FY2025 versus $253M in FY2021, a compound −2.5%/yr. Reported net income was $31.1M in FY2025.
Key figures
Market cap $434M Small · P/E ratio 16.2 · P/S ratio 1.87 · EPS (TTM) $0.5100 · Net margin 10.3% · Return on equity 22.0% · Return on assets (EBIT) 11.4% (5-year average) · Operating margin 9.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 62 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 74% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at 17%, PBYI screens cheaper than that median.
Fair Value models
Bear$7.22Fair Value $9.62Bull$11.96
Price $8.25 · Upside +16.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.4387 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 9 officers or directors sold shares worth $1.7M and none bought.
SaleAlessandra CesanoDirector62,150 shares at $9.12$566,808Sep 14, 202610b5-1 plan
SaleTroy Edward WilsonDirector2× since Jun 12, 2026: 15,800 shares, avg. $7.80$123,260Sep 14, 202610b5-1 plan
SaleMaximo F NouguesChief Financial Officer2× since Jan 6, 2026: 20,331 shares, avg. $6.97$141,703Jul 6, 202610b5-1 plan
SaleDouglas M HuntOfficer2× since Jan 6, 2026: 17,447 shares, avg. $7.02$122,564Jul 6, 202610b5-1 plan
SaleAlan H AuerbachPresident and CEO, Director, 10% owner2× since Jan 6, 2026: 79,008 shares, avg. $7.20$568,748Jul 6, 202610b5-1 plan
SaleAllison DorvalDirector11,610 shares at $7.20$83,592Jun 12, 202610b5-1 plan
SaleJay M MoyesDirector22,000 shares at $7.22$158,840Jun 12, 202610b5-1 plan
SaleAdrian SenderowiczDirector27,000 shares at $7.20$194,400Jun 12, 202610b5-1 plan
SaleBrian M StuglikDirector8,100 shares at $7.20$58,320Jun 12, 202610b5-1 plan
SaleMichael Patrick MillerDirector20,000 shares at $4.86$97,200Nov 11, 2025
Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−0.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.2%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+53.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+53.3%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−14% → 16%
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −2.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score62 · Top 25%
Fair Value upside+16.6% · Top 25%
Profitability
Return on equity (12 months)22.0% · Top 25%
Return on assets14.4% · Top 25%
Net margin (12 months)10.3% · Above median
Operating margin (12 months)9.6% · Above median
Growth and dividend
Revenue growth (quarter YoY)1.1% · Above median
Balance sheet
Debt / equity0.17× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Puma Biotechnology Inc (PBYI) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $9.62 versus a price of $8.25, about +17% upside (undervalued).
What is the fair value of PBYI?
Our model-based fair value for Puma Biotechnology Inc is $9.62 (as of Nov 7, 2026), built from audited fundamentals. The current price: $8.25.
What is the quality score of PBYI?
Puma Biotechnology Inc has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Puma Biotechnology Inc (PBYI)?
Our model-based price target is the fair value of $9.62 (as of Nov 7, 2026) from 22 valuation models. Cautious scenario $7.22, optimistic scenario $11.96. It is a calculation from audited fundamentals, not an analyst target.
What is the Puma Biotechnology Inc stock forecast for 2026?
Our models put fair value at $9.62, about +17% upside versus a price of $8.25 (undervalued). Cautious scenario $7.22, optimistic scenario $11.96. The calculation is refreshed regularly with new filings.
What is the revenue of Puma Biotechnology Inc (PBYI)?
Puma Biotechnology Inc reported trailing-twelve-month revenue of about $232M (latest available figure, as of Nov 7, 2026).
What growth is priced into Puma Biotechnology Inc (PBYI)?
For today's price to be fair in a discounted-cash-flow model, Puma Biotechnology Inc would have to grow free cash flow by +0.2 % per year for five years (discount rate 12.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.3 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of PBYI use?
Our models discount Puma Biotechnology Inc at 12.2 %: a base by market capitalisation (small), damped by beta 1.33, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Puma Biotechnology Inc that is +0.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.2 %) and the same formula as our fair value.
How much growth has Puma Biotechnology Inc (PBYI) delivered so far?
Over the past 5 years revenue at Puma Biotechnology Inc grew +0.3 % a year. The price currently implies free-cash-flow growth of +0.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Puma Biotechnology Inc (PBYI) growing?
The median revenue growth in the sector is +6.3 % a year. That is the yardstick for the growth priced into Puma Biotechnology Inc (+0.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Puma Biotechnology Inc (PBYI)?
The free-cash-flow yield on the price is 9.62 %: that much free cash flow Puma Biotechnology Inc produces per unit of market value. When it exceeds the discount rate of our models (12.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Puma Biotechnology Inc (PBYI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Puma Biotechnology Inc it is $9.62 per share (as of Nov 7, 2026), against a price of $8.25. It is the blended result of 22 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Puma Biotechnology Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, PBYI trades below its calculated fair value: price $8.25, fair value $9.62, a gap of about +17% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PBYI?
No. The price is what the market pays today ($8.25); the fair value is what the company's own numbers justify ($9.62). For Puma Biotechnology Inc the two are $1.37 per share apart. That gap is exactly why we show both numbers side by side.
How much is Puma Biotechnology Inc worth?
The market values Puma Biotechnology Inc at about $434M (market capitalisation, as of Nov 7, 2026). Per share that is $8.25; our models calculate a fair value of $9.62 per share.
What do the bullish and bearish scenarios say about PBYI?
Our models span a range for Puma Biotechnology Inc: cautious scenario $7.22, base $9.62, optimistic $11.96 per share (as of Nov 7, 2026, price $8.25). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PBYI?
Puma Biotechnology Inc trades at a price-to-earnings ratio of 16.2 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $9.62 is built from several models across several years. Other multiples: PEG 0.0, P/B 3.3, P/S 1.9, EV/EBITDA 12.0.
What is the PEG ratio of PBYI?
The PEG ratio of Puma Biotechnology Inc is 0.03 (P/E divided by earnings growth, as of Nov 7, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Puma Biotechnology Inc (PBYI)?
Balance-sheet figures for Puma Biotechnology Inc (as of Nov 7, 2026): return on equity 22.0%, debt of 0.17 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is PBYI from its 52-week high?
Puma Biotechnology Inc trades at $8.25, about 27% below its 52-week high of $11.26 and 74% above the low of $4.73 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $9.62 is for.
Which stocks are comparable to Puma Biotechnology Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Puma Biotechnology Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $8.25, calculated fair value $9.62 (+17%), Quality Score 62/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PBYI calculated?
We run Puma Biotechnology Inc through 22 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $9.62 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Puma Biotechnology Inc currently trades 14% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Puma Biotechnology Inc (PBYI)?
The closing price on Nov 6, 2026 was $8.25. Our model-based fair value is $9.62, about +17% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Puma Biotechnology Inc right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Puma Biotechnology Inc
How large is the market capitalisation of Puma Biotechnology Inc (PBYI)?
The market capitalisation of Puma Biotechnology Inc is $434M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Puma Biotechnology Inc (PBYI)?
The price-to-sales ratio of Puma Biotechnology Inc is 1.87 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Puma Biotechnology Inc (PBYI)?
Earnings per share at Puma Biotechnology Inc are $0.5100 (price ÷ EPS = P/E 16.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Puma Biotechnology Inc (PBYI)?
The net margin of Puma Biotechnology Inc is 10.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Puma Biotechnology Inc (PBYI)?
The return on equity (ROE) of Puma Biotechnology Inc is 22.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Puma Biotechnology Inc (PBYI)?
On an EBIT basis the return on assets of Puma Biotechnology Inc is 11.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Puma Biotechnology Inc (PBYI)?
The operating margin of Puma Biotechnology Inc is 9.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Puma Biotechnology Inc (PBYI)?
Revenue at Puma Biotechnology Inc is growing +1.1% versus a year earlier (3y avg +0.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Puma Biotechnology Inc (PBYI)?
Earnings per share at Puma Biotechnology Inc are growing −35.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Puma Biotechnology Inc (PBYI) hold?
Puma Biotechnology Inc holds more cash than debt, $1.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Puma Biotechnology Inc in the live analysis
One click puts Puma Biotechnology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 7, 2026